Key Developments For Caliper Life Sciences, Inc.
Caliper Life Sciences, Inc. (CALP.O) (Consolidated Issue listed on NASDAQ Global Market)
Caliper Life Sciences Inc. Raises Low End Of Prior FY 2009 Revenue Guidance; Reaffirms H2 2009, FY 2010 Earnings Guidance; Issues Q4 2009 Revenue Guidance Below Analysts' Estimates
Caliper Life Sciences Inc. announced that for fiscal 2009, it expects revenue of $127-$129 million, which represents organic revenue growth of 5% to 7% over 2008 pro forma revenue. In addition, the Company reaffirmed its expectation to achieve positive earnings before interest, taxes, depreciation, amortization and stock-based compensation over the second half of 2009 and for the fiscal 2010. Caliper reported that its revenue outlook for the fourth quarter of 2009 is $34.5-$36.5 million compared to pro forma revenue (net of divestitures) of $34.6 million in the fourth quarter of 2008. According to Reuters Estimates, analysts were expecting the Company to report revenues of $128 million for fiscal 2009; revenues of $38.6 million for fourth quarter of 2009; EBITDA of $3.30 million for fiscal 2010.
Caliper Life Sciences Inc. Receives New Task Order For EPA ToxCast Program
Caliper Life Sciences Inc. announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $1.8 million under its contract with the Environmental Protection Agency (EPA) for the EPA's ToxCast screening program. This new task order increases the cumulative funding Caliper has been awarded under the ToxCast program to $5.6 million.
Caliper Life Sciences Inc. Reaffirms FY 2009 Organic and GAAP Revenue Guidance; Lowers Q3 2009 Revenue Guidance; Comments On H2 2009 and 2010 EBITDA Guidance-Conference Call
Caliper Life Sciences Inc. announced that for fiscal 2009, it expects 5% to 7% organic growth and GAAP revenues to be in the range of $126-$129 million. For the third quarter of 2009, the Company expects revenue of $20 million compared to earlier forecast of $28-$32 million. The Company expects positive EBITDA in the second half of 2009 and 2010, as stated earlier. According to Reuters Estimates, analysts were expecting the Company to report revenue of $128 million for fiscal 2009; revenue of $29 million for the third quarter of 2009.
Caliper Life Sciences Inc. Issues Q3, FY 2009 Revenue Guidance In Line With Analysts' Estimates
Caliper Life Sciences Inc. announced that for third quarter of 2009, it expects revenue to be in the range of $28 to $32 million. For fiscal 2009, it expects revenue to be in the range of $126 to $129 million. According to Reuters Estimates, analysts are expecting the Company to report revenue of $31 million for third quarter of 2009; revenue of $126 million for fiscal 2009.
Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences Inc.
Caliper Life Sciences Inc. announced that a collaboration with the Peter MacCallum Cancer Centre (PMCC), based in Melbourne, Victoria, Australia. PMCC is using the Company's Staccato automation system to perform oncology related lab discovery experiments in less time, leading to a better understanding of how to treat and prevent cancer through gene knockdown therapies.
